ProCE Banner Activity

CME

Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer

Podcast Episodes

Discussion between experts on novel and emerging HER2-targeted and TROP-2–directed therapies for patients with HER2-low, hormone receptor–positive, and triple-negative advanced breast cancer.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: March 20, 2024

Expiration: March 19, 2025

Share

Faculty

Melinda Telli

Melinda Telli, MD

Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This program is intended for oncologists and other healthcare professionals who care for patients with breast cancer.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, competence, and performance in integrating novel HER2-directed and TROP-2–targeted therapies, emerging clinical data, and treatment-related AE management into clinical practice for the treatment of HER2-low, HR-positive, and triple-negative breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Analyze and integrate therapeutic strategies for patients with HER2-low MBC based on a comprehensive understanding of available clinical data and expert recommendations.

  • Apply guideline-recommended testing and assessment of HER2 expression to broaden the scope of HER2-targeted treatment options, particularly for patients previously classified as HER2 negative

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Melinda Telli, MD

Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California

Melinda Telli, MD: consultant/advisor/speaker: AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Genentech, GlaxoSmithKline, Guardant, Merck, Natera, Novartis, Pfizer, RefleXion, Replicate, Sanofi Aventis; data safety monitoring committee: Gilead, G1 Therapeutics.

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, ARC Therapeutics, Artios Pharma, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, eFFECTOR Therapeutics, Eisai, Eli Lilly, Genentech/Roche, Gilead, Hengrui USA, Incyte Corp, Infinity Therapeutics, Jazz Pharmaceuticals, Menarini/Stemline, Merck, Natera, Novartis, OncXerna, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Sumitovant Biopharma, Systimmune, Tango Therapeutics, Umoja Biopharma, Zentalis, Zetagen, Zymeworks; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer, Seattle Genetics.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 20, 2024, through March 19, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.